Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Alexa J Loncharich, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Kari Wilson, Mark A. Schroeder, Keith E Stockerl-Goldstein, Ravi Vij, Kristen M. Sanfilippo

Blood (2022) 140 (Supplement 1): 8550–8551.

https://doi.org/10.1182/blood-2022-166736

Published: 2022

Journal Articles

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

Jacob Edmisson, Mark A Fiala, Michael J Slade, Angela Vickroy, Margaret Kavanaugh, Carmen Wilson, Jingyu Xiang, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, John F. DiPersio, Ravi Vij

Blood (2022) 140 (Supplement 1): 4295–4296.

https://doi.org/10.1182/blood-2022-169367

Published: 2022

Journal Articles

A Novel Serum Free Light Chain Metric Provides Greater Diagnostic Specificity and Robustness to Variation in Renal Function

Vahid Azimi, Michael J Slade, Mark A Fiala, Julie M Fortier, Keith E Stockerl-Goldstein, John L Frater, Jonathan R Brestoff, Ronald Jackups, Jr., Mark A Zaydman

Blood (2022) 140 (Supplement 1): 7160–7161.

https://doi.org/10.1182/blood-2022-167588

Published: 2022

Journal Articles

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Michael J Slade, Abir Khalid, Mark A Fiala, Mariya Liyasova, Mark A Zaydman, Zac McDonald, Julie M Fortier, Sarah Kelley, Zachary D. Crees, Mark A. Schroeder, Keith E Stockerl-Goldstein, Liqiang Yang, Ravi Vij

Blood (2022) 140 (Supplement 1): 4376–4377.

https://doi.org/10.1182/blood-2022-155582

Published: 2022

Journal Articles

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Blood (2022) 140 (Supplement 1): 1875–1876.

https://doi.org/10.1182/blood-2022-157214

Published: 2022

Journal Articles

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

Blood (2022) 139 (8): 1177–1183.

https://doi.org/10.1182/blood.2021011532

Published: 2022

Includes: Supplemental data

Journal Articles

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Ramzi Abboud, Feng Gao, Michael P. Rettig, Jeremy Eisele, Leah Gehrs, Nichols Wallace, Camille Abboud, Sr., Peter Westervelt, Geoffrey L. Uy, Amanda F. Cashen, Matt Christopher, Armin Ghobadi, Meagan A. Jacoby, Iskra Pusic, Keith E. Stockerl-Goldstein, John F. DiPersio, Mark A. Schroeder

Blood (2021) 138 (Supplement 1): 100.

https://doi.org/10.1182/blood-2021-144591

Published: 2021

Journal Articles

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Zachary D. Crees, Michael Retting, Reyka G Jayasinghe, Keith E. Stockerl-Goldstein, Abi Vainstein, Ella Sorani, Debby Ickowicz, Liron Shemesh-Darvish, Shaul Kadosh, John F. DiPersio

Blood (2021) 138 (Supplement 1): 3816.

https://doi.org/10.1182/blood-2021-144297

Published: 2021

Journal Articles

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

Blood (2021) 138 (Supplement 1): 475.

https://doi.org/10.1182/blood-2021-144296

Published: 2021

Journal Articles

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

Meagan A. Jacoby, David A. Sallman, Bart L. Scott, Megan Haney, Fei Wan, John F. DiPersio, Ramzi Abboud, Keith E. Stockerl-Goldstein, Rami S. Komrokji, Mark A. Schroeder, Matthew J. Walter, Peter Westervelt, Geoffrey L. Uy

Blood (2021) 138 (Supplement 1): 540.

https://doi.org/10.1182/blood-2021-151137

Published: 2021

Journal Articles

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Blood (2021) 138 (Supplement 1): 2849.

https://doi.org/10.1182/blood-2021-146783

Published: 2021

Journal Articles

Financial Toxicity Among Patients with Multiple Myeloma

Alice Silberstein, Mark A. Fiala, Sarah Kelley, Mark A. Schroeder, Keith E. Stockerl-Goldstein, Ravi Vij

Blood (2021) 138 (Supplement 1): 4027.

https://doi.org/10.1182/blood-2021-153653

Published: 2021

Journal Articles

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Lawrence Liu, MD, Gao Feng, MD PhD MPH, Mark A. Fiala, MSW, Justin King, BS, Scott R. Goldsmith, MD, Tanya M. Wildes, MD MSCI, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS, Mark A. Schroeder, MD

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137023

Published: 2020

Journal Articles

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Samuel Rubinstein, MD, Ryan C. Lynch, MD, Aakash Desai, MD, Catherine Stratton, MPH, Alokkumar Jha, PhD, Ziad Bakouny, MD MSc, Andrew Schmidt, MD, R. Alejandro Sica, MD, Divaya Bhutani, MD, Dimpy P. Shah, MD PhD, Sarah A Wall, MD, Gary H. Lyman, MD, Nicole M. Kuderer, MD MSc, Matthias Weiss, MD PhD, Jeremy L. Warner, MD MS, Keith E. Stockerl-Goldstein, MD, Ruben Mesa, MD, Michael A. Thompson, MD PhD

Blood (2020) 136 (Supplement 1): 28–30.

https://doi.org/10.1182/blood-2020-141937

Published: 2020

Journal Articles

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

Amrita Y. Krishnan, MD, Krina K. Patel, MD MSc, Parameswaran Hari, MBBS, MD, Sundar Jagannath, MD, Ruben Niesvizky, MD, Rebecca W. Silbermann, MD, Deborah Berg, RN, MSN, Jianchang Lin, PhD, Eric Robert Fedyk, BSc, MSc, PhD, Antonio Palumbo, MD, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 140.

https://doi.org/10.1182/blood-2019-128007

Published: 2019

Journal Articles

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Scott R. Goldsmith, MD, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya M. Wildes, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Keith E. Stockerl-Goldstein, MD

Blood (2019) 134 (Supplement_1): 4351.

https://doi.org/10.1182/blood-2019-131135

Published: 2019

Journal Articles

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

Justin King, Mark A. Fiala, BS, Scott R. Goldsmith, MD, Keith E. Stockerl-Goldstein, MD, Mark A. Schroeder, MD, Armin Ghobadi, MD, Ravi Vij, MBBS, Tanya M. Wildes, MD

Blood (2019) 134 (Supplement_1): 5701.

https://doi.org/10.1182/blood-2019-130689

Published: 2019

Journal Articles

The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients

Brandon B. Wang, Mark A. Fiala, BS, Mark A. Schroeder, MD, Tanya Wildes, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 3439.

https://doi.org/10.1182/blood-2018-99-111379

Published: 2018

Journal Articles

The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma

Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 4463.

https://doi.org/10.1182/blood-2018-99-118660

Published: 2018

Journal Articles

Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study

Angela Vickroy, ANP, Adam Kent Peery, BS,ANP, Mark A. Fiala, BS, Tanya M. Wildes, MD MSCI, Mark A. Schroeder, MD, Armin Ghobadi, MD, Keith E. Stockerl-Goldstein, MD, Ravi Vij, MBBS

Blood (2018) 132 (Supplement 1): 5666.

https://doi.org/10.1182/blood-2018-99-119589

Published: 2018

NARROW

Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma

A Novel Serum Free Light Chain Metric Provides Greater Diagnostic Specificity and Robustness to Variation in Renal Function

Clonotypic Mass Spectrometry with Easym Assay for Detection of Measurable Residual Disease in Multiple Myeloma

Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy

A Single-Arm, Open-Label, Pilot Study of the JAK1 Selective Inhibitor Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome in T-Cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation

Immunophenotypic and Single-Cell Transcriptional Profiling of CD34+ Hematopoietic Stem and Progenitor Cells Mobilized with Motixafortide (BL-8040) and G-CSF Versus Plerixafor and G-CSF Versus Placebo and G-CSF: A Correlative Study of the Genesis Trial

Motixafortide (BL-8040) and G-CSF Versus Placebo and G-CSF to Mobilize Hematopoietic Stem Cells for Autologous Stem Cell Transplantation in Patients with Multiple Myeloma: The Genesis Trial

A Pilot Study of CPX-351 (Vyxeos © ) for Transplant Eligible, Higher Risk Patients with Myelodysplastic Syndrome

Hematopoietic Cell Transplantation of Higher CD34+ Cell Doses and Specific CD34+ Subsets Mobilized with Motixafortide and/or G-CSF Is Associated with Rapid Engraftment - a Post-Hoc Analysis of the Genesis Trial

Financial Toxicity Among Patients with Multiple Myeloma

A Single Center Retrospective Analysis of Daratumumab, Pomalidomide, and Dexamethasone As a Second Line Therapy for Multiple Myeloma

Severity of Sars-Cov-2 Infection in Patients with Hematologic Malignancies: A COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Preliminary Results from a Phase 1b Study of TAK-079, an Investigational Anti-CD38 Monoclonal Antibody (mAb) in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM)

The Ire of IRE1α: Overexpression of IRE1α at Myeloma Diagnosis Is Associated with Decreased Survival While Downregulation of IRE1α Expression Is Predictive of Therapy Resistance

Utilization of Autologous Stem Cell Transplantation in Older Patients with Newly Diagnosed Multiple Myeloma

The Effect of Maintenance Therapy Following Salvage Autologous Stem Cell Transplant in Multiple Myeloma Patients

The Characteristics, Treatment Patterns, and Outcomes of Older Adults with Multiple Myeloma

Increasing Daratumumab Frequency As a Way to Restore Responses- a Retrospective Case Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only